This possibility was recently used to treat PTSD in an animal model by reactivating the trauma memory while the possibility of expressing an emotional response was reduced by a pharmacological treatment, a paradigm that we termed “emotional remodeling.” More specifically, we showed that delivering drugs such as amphetamine or oxytocin, before the reactivation of the trauma memory, may abolish PTSD symptoms in trauma vulnerable rats (Toledano and Gisquet-Verrier, 2014; Le Dorze et al., submitted). The gene discussed is OXT; the disease is post-traumatic stress disorder.